PDE4 inhibitor
Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD
... oral PDE4 inhibitor roflumilast [3–6], with a lack of effect on symptoms also common [5, 6], while two other inhaled PDE4 inhibitors did not show consistent effects on lung func- tion [24, ...
12
Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD
... patients receiving concomitant ICS may be a marker of disease severity. This patient subgroup is at higher risk for exacerbations, indicated by the higher exacerbation rate in the placebo group in ICS-treated patients vs ...
10
Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors
... Targeting PDE4 has enormous clinical potential due to its mechanism of action, which leads to increased intra- cellular cAMP levels in many different inflammatory cells, decreasing T cell and monocyte-derived ...
13
Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor alpha from human rheumatoid synovial cells and ameliorates experimental arthritis
... several PDE4 inhibitors have been tested in experimental arthritis due to their potent capacity to inhibit TNFα production in a range of cell types ...of PDE4 inhibitors in experimental arthritis ...PDE7/ ...
11
Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis
... In addition, differentially regulated genes, pathways, biological processes and molecular functions were considered significant only upon correction for multiplicity (pFDR< 0.05). Few[r] ...
11
Targeting phosphodiesterase 4 as a potential therapeutic strategy for enhancing neuroplasticity following ischemic stroke
... [83]. PDE4 inhibitors has caused extensive concern as they are expected to modulate a variety of cellular functions, including neuroplasticity and neuroprotection ...three PDE4 isoforms (PDEA, B, D) ...
10
Recent Developments in Atopic Dermatitis
... (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): a phase-II randomized, double-blind, placebo-controlled ...
14
Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases
... Fig. 3. MR-L2 reduces intracellular cAMP in MDCK cells without affecting PDE4 expression or cell viability. (A) MDCK cells were grown in 2D culture and treated with increasing concentrations of MR-L2. Western blot ...
10
Triple negative breast cancer development can be selectively suppressed by sustaining an elevated level of cellular cyclic AMP through simultaneously blocking its efflux and decomposition
... PDE inhibitor 3-isobutyl-1-methyl-xanthene ...multiple PDE4 isotypes can diminish cellular cAMP when MRPs are ...(pan-MRP inhibitor) and rolipram (PDE4 inhibitor) effectively inhibit in ...
14
Phosphodiesterase 4-targeted treatments for autoimmune diseases
... the PDE4 inhibitor class to be FDA ...selective PDE4 inhibitor is licensed for oral, once-daily treatment of severe chronic obstruc- tive pulmonary disease ...
8
A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice
... with PDE4 inhibitors, with the goal of maintaining or enhancing efficacy while reducing the dose-limiting side effects associated with these drugs ...the PDE4 inhibitor rolipram was enhanced by a ...
14
PDE4 as a target in preterm labour
... of PDE4 in the nonpregnant state and near ...Selective PDE4 inhibitors of the first (rolipram) and of the most recent developed generation achieve a complete relaxation of the myometrial strips, either in ...
5
ajplung.00324.2015.pdf
... stimulation. PDE4-dependent compartmentalization of cAMP in Calu-3 airway epithelial cells was reported by Barnes et ...of PDE4, but not PDE3, can abolish the lateral confinement of cAMP signals that are ...
12
Integrating a Next Generation Sequencing Panel into Clinical Practice in Ovarian Cancer
... Results: Of the 84 patients, 55 (65.1%) had high-grade serous carcinomas. Seventy-three (86.7%) patients underwent NGS at the time of diagnosis, and 11 (13.3%) underwent NGS upon relapse. The most common genetic ...
10
Crisaborole and Apremilast: PDE4 Inhibitors with Similar Mechanism of Action, Different Indications for Management of Inflammatory Skin Conditions
... a PDE4 inhi- bitor in an ointment base also provides the barrier protection and skin hydration requirements for AD therapy along with the additional anti-inflammatory ac- tions associated with increases in ...
25
In Silico Designing of Novel Thiazolidine-2-one Derivatives as Dual PDE4/7 Inhibitors for Inflammatory Disorders
... of PDE4 and PDE7 produced a similar binding pattern and superposition on the binding mode of co-crystallized inhibitors validating accuracy of docking ...of PDE4 and PDE7 proteins; and most of the designed ...
14
Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells
... where PDE4 genes were found to be differentially ...and PDE4 represented the major cAMP hydrolyzing enzymes, the contribution of PDE4 being greater than that of ...and PDE4 predominate, but ...
12
kNN-MFA-guided 3D-QSAR on Some PDE4 Inhibitors of Benzylamine derivatives For Chronic Obstructive Pulmonary Disease
... Benzylamine derivatives have recently been demonstrated interesting potential as the treatment for chronic obstructive pulmonary disease via interaction with the PDE4 enzymes. To understand the necessity around ...
7
Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells
... erlotinib, and 50 nM cetuximab or 30 nM of the mixture of siRNA for indicated time periods and washed 3 times. Cell lysates was obtained by incubating the cells in a lysis buffer [10 mM Tris pH 6.8, 1 mM EDTA, 10% NP40, ...
10
Dimerization of cAMP phosphodiesterase-4 (PDE4) in living cells requires interfaces located in both the UCR1 and catalytic unit domains
... length PDE4 isoforms has militated against structural studies of such physiologically relevant species, there is a wealth of 3-D structural data on truncated species that represents the highly conserved core ...
14